#RNL2023 @anisha_dua: Temporary artery biopsy still preferred, rec over u/s, especially if not Early imaging for GCA recommended @RheumNow https://t.co/41fiQuj2x9

"Ideally, you should get your TA biopsies within 2 weeks, but that's not always possible. Don't delay tx." @anisha_dua reminds us that bx can still be positive up to 8 weeks after steroid initiation. Just be aware of lesional changes with time. #RNL2023 @RheumNow https://t.co/uOdmlLfdkh

A reminder by @anisha_dua ➡️15% #PMR patients get #GCA ➡️ up to 50% GCA patients get PMR #RNL2023

GCA biopsy: When and How Early is best, rec'd in first 2 weeks. Findings can be present at 8 weeks but be less prominent @anisha_dua rec's unilateral imaging in most pts, especially w scalp tenderness on one side >1 cm length #RNL2023 @RheumNow https://t.co/HBHBGeFm6J

Highest pre-test probability for GCA is actually: 1) Limb claudication 2) Jaw claudication #RNL2023 @RheumNow https://t.co/13tDXMhJKM

@anisha_dua shares her take home points for PMR. Check out her great review below! #RNL2023 @rheumnow https://t.co/PAqXaXcXAb

@anisha_dua Table on imaging in LVV U/S: increase specificity for PMR, operator dependent CTA: high detail, contrast + radiation MRA: cost and limitations in CKD, metal PET/CT: useful but not specific for vasculitis and very high cost #RNL2023 @RheumNow https://t.co/aTdrlPfN9J

Long-Term Survival of Idiopathic Inflammatory Myopathies A single center cohort study analyzed the outcome and survival of IIM patients and showed good 5 and 10 year survival but showed significant declined 15-25 years post-diagnosis. https://t.co/oEuTNiUANc https://t.co/1lXiStqoEz

• https://bit.ly/3Fx8OYX

Should be revisit role of #MTX in OA? Possibly some benefit in metabolically active #osteoarthritis #RNL2023 #methotrexate https://t.co/DIxIYQNulv

MTX as a treatment of OA, by Dr.Conaghan #RNL2023 ⁦@RheumNow⁩ Systemic inflammation might also be a part of OA?! https://t.co/grxMKtRLhj

⚠️Only 12-43% of #PsA patients achieved remission or very low disease activity From systematic review in RWE presented by @DrLauraCoates #RNL2023

Treat to target approach in PsA Systematic rev: 12-43% pts achieved target of very low disease activity or remission Pts and docs agree: remission is primary goal, but Low disease activity is acceptable alternative @DrLauraCoates at #RNL2023 @Rheumnow https://t.co/hA7JDR7Zyh

I love a good graphic. Check out @DrLauraCoates’ review of the impact of MDA in PSAID scores in PsA. #RNL2023 @RheumNow https://t.co/iQYuLQobXL

Treat to target in PSA: What's difference in our outcome scores? DAPSA: includes CRP MDA: includes enthesitis, skin, function Both metrics include Tender/Swollen jt counts, and pt pain/global Presented by @DrLauraCoates at #RNL2023 @RheumNow https://t.co/7i5m70HGiz

Dr. Laura Coates presents - Is remission in PsA attainable? systematic review: 12-43% achieved very low disease activity or remission #RNL2023 @RheumNow https://t.co/flfpzc7B4p